Price T Rowe Associates Raised Immunogen (IMGN) Position by $6.35 Million; As Ally Financial (ALLY) Share Price Declined, Oregon Public Employees Retirement Fund Boosted Stake

January 18, 2018 - By Vivian Park

Oregon Public Employees Retirement Fund increased its stake in Ally Financial Inc (ALLY) by 23.68% based on its latest 2017Q3 regulatory filing with the SEC. Oregon Public Employees Retirement Fund bought 15,531 shares as the company’s stock declined 19.04% while stock markets rallied. The institutional investor held 81,114 shares of the consumer services company at the end of 2017Q3, valued at $1.97 million, up from 65,583 at the end of the previous reported quarter. Oregon Public Employees Retirement Fund who had been investing in Ally Financial Inc for a number of months, seems to be bullish on the $13.51B market cap company. The stock decreased 0.23% or $0.07 during the last trading session, reaching $30.55. About 1.47 million shares traded. Ally Financial Inc. (NYSE:ALLY) has risen 12.72% since January 18, 2017 and is uptrending. It has underperformed by 3.98% the S&P500.

Price T Rowe Associates Inc increased its stake in Immunogen Inc (IMGN) by 3283.76% based on its latest 2017Q3 regulatory filing with the SEC. Price T Rowe Associates Inc bought 907,500 shares as the company’s stock rose 116.05% with the market. The institutional investor held 935,136 shares of the health care company at the end of 2017Q3, valued at $7.15 million, up from 27,636 at the end of the previous reported quarter. Price T Rowe Associates Inc who had been investing in Immunogen Inc for a number of months, seems to be bullish on the $1.07 billion market cap company. The stock decreased 2.06% or $0.17 during the last trading session, reaching $8.09. About 1.19M shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has declined 3.49% since January 18, 2017 and is downtrending. It has underperformed by 20.19% the S&P500.

Among 8 analysts covering Immunogen (NASDAQ:IMGN), 5 have Buy rating, 1 Sell and 2 Hold. Therefore 63% are positive. Immunogen had 25 analyst reports since August 3, 2015 according to SRatingsIntel. Cantor Fitzgerald downgraded ImmunoGen, Inc. (NASDAQ:IMGN) on Monday, August 3 to “Neutral” rating. The company was maintained on Wednesday, August 30 by Canaccord Genuity. The stock has “Buy” rating by Jefferies on Sunday, August 6. Jefferies maintained the shares of IMGN in report on Friday, November 3 with “Buy” rating. The stock has “Outperform” rating by Oppenheimer on Wednesday, July 29. Cantor Fitzgerald maintained ImmunoGen, Inc. (NASDAQ:IMGN) on Tuesday, May 30 with “Hold” rating. The firm earned “Buy” rating on Wednesday, November 25 by Jefferies. The stock has “Outperform” rating by RBC Capital Markets on Thursday, July 6. Jefferies maintained ImmunoGen, Inc. (NASDAQ:IMGN) on Friday, September 8 with “Buy” rating. The rating was maintained by Canaccord Genuity with “Buy” on Friday, November 3.

Investors sentiment decreased to 1.16 in Q3 2017. Its down 0.04, from 1.2 in 2017Q2. It turned negative, as 16 investors sold IMGN shares while 48 reduced holdings. 38 funds opened positions while 36 raised stakes. 87.70 million shares or 19.45% more from 73.42 million shares in 2017Q2 were reported. Vanguard Group has 0% invested in ImmunoGen, Inc. (NASDAQ:IMGN). Great West Life Assurance Can reported 9,004 shares or 0% of all its holdings. Creative Planning holds 0% or 35,750 shares. 5.61M are held by Fmr Ltd Liability. Stifel has invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Alexandria Cap Ltd Com holds 0% or 16 shares in its portfolio. Goldman Sachs Gp has invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Natixis owns 10,541 shares. Contravisory Management owns 0% invested in ImmunoGen, Inc. (NASDAQ:IMGN) for 73 shares. Palisade Capital Mngmt Ltd Com Nj invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Raymond James Fincl accumulated 22,648 shares. Morgan Stanley invested in 0% or 988,509 shares. Primecap Management Ca invested in 3.82M shares or 0.02% of the stock. Cornerstone stated it has 250 shares or 0% of all its holdings. Ubs Asset Americas holds 50,239 shares.

Since September 13, 2017, it had 0 insider purchases, and 2 insider sales for $262,957 activity. BARROWS CRAIG sold $252,457 worth of ImmunoGen, Inc. (NASDAQ:IMGN) on Wednesday, September 13.

Price T Rowe Associates Inc, which manages about $585.46 billion US Long portfolio, decreased its stake in Spartannash Co (NASDAQ:SPTN) by 14,700 shares to 1.64 million shares, valued at $43.27M in 2017Q3, according to the filing. It also reduced its holding in Las Vegas Sands Corp (NYSE:LVS) by 2.25M shares in the quarter, leaving it with 7.88M shares, and cut its stake in Peoples United Financial Inc (NASDAQ:PBCT).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com